Effect of a Tranexamic Acid, Kojic Acid, and Niacinamide Containing Serum on Facial Dyschromia: A Clinical Evaluation

May 2019 | Volume 18 | Issue 5 | Original Article | 454 | Copyright © May 2019


Seemal Desai MD,a,b Eloisa Ayres MD,c Hana Bak MD,d,e Megan Manco MS,f Stephen Lynch PhD,g Susana Raab MS,g Ana Du BS,g DesTenee Green BS,g Cezary Skobowiat PhD,g Janet Wangari-Talbot PhD,g Qian Zheng MD PhDg

aUniversity of Texas Southwestern Medical Center, Dallas, TX bInnovative Dermatology, Plano, TX cEZSkin Dermatologia, Niterói, Rio de Janeiro, Brazil dCheongdam-Hana Dermatology, Seoul, Korea eYonsei University Wonju College of Medicine, Wonju, Korea fSkinceuticals, New York, NY gL’Oréal Research and Innovation, Clark, NJ

9. K. Shankar, K. Ghodse, Aurangabadker S, et al. Evidence-based treatment for melasma: expert opinion and a review. Dermatol Ther (Heidelb). 2014;4(2):165–186.10. Deo KS, Dash KN, Sharma YK, Virmani NC, Oberai C. Kojic acid vis-a-vis its combinations with hydroquinone and betamethasone valerate in melasma: a randomized, single blind, comparative study of efficacy and safety. Indian J Dermatol. 2013;58(4):281-5.11. Monteiro RC, Kishore BN, Bhat RM, Sukumar D, Martis J, Ganesh HK. A comparative study of the efficacy of 4% hydroquinone vs 0.75% kojic acid cream in the treatment of facial melasma. Indian J Dermatol. 2013;58(2):157.12. Navarrete-Solís J, Castanedo-Cázares JP, Torres-Álvarez B, Oros-Ovalle C, Fuentes-Ahumada C, González FJ, Martínez-Ramírez JD, Moncada B. A double- blind, randomized clinical trial of niacinamide 4% versus hydroquinone 4% in the treatment of melasma. Dermatol Res Pract. 2011;2011:379173.13. Rolfe HM. A review of nicotinamide: treatment of skin diseases and potential side effects. J Cosmet Dermatol. 2014;13(4):324-8.14. Tse, T. W., & Hui, E. Tranexamic acid: An important adjuvant in the treatment of melasma. J Cosmet Dermatol. 2013;12(1):57-66.15. Byun SY, Chae JB, Na JI, Park KC. Significant improvement in crow’s feet after treatment with Jet-M and a mixed solution of copper–GHK, oligo-hyaluronic acid, rhodiolar extract, tranexamic acid, and beta-glucan (GHR formulation). J Cosmet Laser Ther. 2016;18(5):293–5.16. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects (1964). Bull. World Health Org. 2001; 79(4): 373-374.17. Lee JH, Park JG, Lim SH, Kim JY, Ahn KY, et al. Localized intradermal microinjection of tranexamic acid for treatment of melisma in Asian patients: a preliminary clinical trial. Dermatol Surg. 2006;32:626-631.18. Maeda K, Naganuma M. Topical trans-4-aminomethyl cyclohexanecarboxylic acid prevents ultraviolet radiation-induced pigmentation. J Photochem Photobiol B. 1998;47:136-141.19. Kondou S, Okada Y, Tomita Y. Clinical study of effect of tranexamic acid emulsion on melasma and freckles. Skin Res. 2007;6:309-315.20. Na JI, Choi SY, Yang SH, Choi HR, Kang HY, et al. Effect of tranexamic acid on melasma: a clinical trial with histological evaluation. J Eur Acad Dermatol Venereol. 2013;27:1035-1039.21. Nijo T. Treatment of melasma with tranexamic acid. Clin Res. 1979;13:3129- 3131.22. Shital P. and Khushboo M. Tranexamic acid in melasma: a review. J Pigment Disord. 2015;2(12):1-4.23. Starner RJ, McClelland L, Abdel?Malek Z, Fricke A, Scott G. PGE(2) is a UVR?inducible autocrine factor for human melanocytes that stimulates tyrosinase activation. Exp Dermatol. 2010;19:682-4.24. Kang-Rotondo CH1, Miller CC, Morrison AR, Pentland AP. Enhanced keratinocyte prostaglandin synthesis after UV injury is due to increased phospholipase activity. Am J Physiol. 1993;C396-401.

AUTHOR CORRESPONDENCE

Stephen Lynch PhD stephen.lynch@rd.loreal.com